Wegovy (semaglutide 2.4 mg) should be stopped at least two months before you plan to become pregnant. The manufacturer's prescribing information is clear on this point. However, the significant weight loss Wegovy provides can meaningfully improve fertility outcomes for patients whose reproductive health has been affected by excess weight. Balancing treatment timing with family planning is something to discuss with your provider early on.

Because Wegovy is specifically approved for chronic weight management, its patient population includes many women of childbearing age. Fertility questions are among the most frequently asked in clinical consultations for this medication.

Stopping Wegovy Before Pregnancy

Wegovy contains semaglutide at the 2.4 mg weekly dose, the same active ingredient found in Ozempic but at a higher concentration. Semaglutide has a half-life of approximately seven days, and the two-month discontinuation window allows the drug to clear through roughly eight half-life cycles.

Animal reproductive studies showed adverse fetal outcomes at high doses, including embryonic loss and developmental abnormalities. These findings occurred at exposures well above normal human doses, but because human pregnancy data is scarce, the precautionary washout period is strongly recommended.

Weight Loss and Reproductive Health Benefits

Wegovy produces average weight loss of approximately 15% of starting body weight in clinical trials. For patients whose fertility is compromised by obesity, this level of weight reduction can be transformative:

• Hormonal balance improves as excess fat tissue (which produces estrogen) decreases
• Ovulatory function may resume in women with anovulatory cycles
• Insulin resistance decreases, supporting better reproductive hormone signaling
• Pregnancy complication risks (gestational diabetes, preeclampsia) are reduced at a healthier weight
• Assisted reproduction success rates tend to improve with lower BMI

Some fertility specialists now recommend a period of Wegovy-assisted weight loss followed by a washout window before patients begin active conception attempts or fertility treatments.

Unexpected Fertility Restoration

One of the most discussed aspects of GLP-1 medications and fertility is the unexpected return of ovulation. Women with longstanding PCOS or obesity-related anovulation may begin ovulating again as they lose weight on Wegovy, sometimes without realizing it. This has led to unplanned pregnancies in women who believed they were infertile.

If you are taking Wegovy and do not wish to become pregnant, reliable contraception is essential throughout treatment. Do not assume that past difficulty conceiving means you cannot become pregnant while on this medication.

Contraception Considerations

Wegovy slows gastric emptying, which could theoretically reduce the absorption of oral contraceptive pills. While the clinical significance of this interaction is not definitively established for semaglutide, some providers recommend using a non-oral backup method or switching entirely to a non-oral contraceptive during treatment. Options like hormonal IUDs, implants, and contraceptive injections bypass the GI tract entirely and are unaffected by gastric motility changes.

Frequently Asked Questions